WHO recommendation COVID-19 mRNA vaccine (nucleoside modified) – COMIRNATY® 

WHO assessed the Comirnaty, COVID-19 mRNA vaccine (nucleoside modified) submitted by Pfizer under the Emergency Use Listing (EUL). The vaccine is expected to be an important tool in response to the COVID-19 pandemic. Based on the available evidence assessed, WHO find that sufficient data is available on the Comirnaty, COVID-19 mRNA vaccine (nucleoside modified) for an EUL recommendation.

Comirnaty, COVID-19 mRNA vaccine (nucleoside modified) is a vaccine for preventing coronavirus disease 2019 (COVID-19) in individuals aged 16 years and older. The vaccine contains a molecule called messenger RNA (mRNA) with instructions for producing a protein from SARS-CoV-2, the virus that causes COVID-19. Novel Covid-19 mRNA vaccine does not contain the virus itself and cannot cause COVID-19.

The use of Comirnaty, COVID-19 mRNA vaccine (nucleoside modified) under an emergency situation has been also endorsed by the European Medicines Agency (EMA), the Food and Drug Administration of the United States of America and Health Canada and other regulatory authorities (including Bahrain, Israel, Kuwait, Mexico, Oman, Qatar, Saudi Arabia, Singapore and the United Kingdom).

Source. World Health Organization (WHO)